THOMAS P. NIGRA, MD
Dermatology at Irving St, Washington, DC
License number
DC MD25748
Category
Osteopathic Medicine
Type
Dermatology
Address
Address
110 Irving St NW SUITE 2A38, Washington, DC 20010
Phone
(202) 877-6227
(202) 877-3288 (Fax)
(202) 877-3288 (Fax)
Personal information
See more information about THOMAS P. NIGRA at radaris.comName
Address
Phone
3038 N N St NW, Washington, DC 20007
Washington, DC
3038 North Street Nw, Washington, DC 20007
3038 St, Washington, DC 20007
3038 St Nw, Washington, DC 20007
Organization information
See more information about THOMAS P. NIGRA at bizstanding.comDermatology Associates - Thomas P Nigra MD
110 Irving St NW #2B44, Washington, DC 20010
Categories:
Dermatology Physicians & Surgeons, Physicians & Surgeons
Phone:
(202) 877-6654 (Phone)
Thomas P Nigra MD PC
110 Irving St NW, Washington, DC 20010
Industry:
Medical Doctor's Office
Medical Doctor:
Thomas Nigra (Medical Doctor)
Professional information
See more information about THOMAS P. NIGRA at trustoria.com
Thomas P Nigra, Washington DC
Thomas P Nigra, Washington DC
Specialties:
Dermatologist
Address:
110 Irving St Nw, Washington, DC 20010
Education:
University of Pennsylvania, Perelman School of Medicine - Doctor of Medicine*
National Institutes of Health-Clinical Center - Residency - Dermatology*
Massachusetts General Hospital - Residency - Dermatology*
National Institutes of Health-Clinical Center - Residency - Dermatology*
Massachusetts General Hospital - Residency - Dermatology*
Board certifications:
American Board of Dermatology Certification in Dermatology*
Chairman Of Dermatology At Georgetown/Washington Hospital Center
Chairman Of Dermatology At Georgetown/Washington Hospital Center
Position:
Dermay at Washington hospital centerl
Location:
Washington D.C. Metro Area
Industry:
Health, Wellness and Fitness
Work:
Washington hospital centerl
-
Dermay
Dr. Thomas P Nigra, Washington DC - MD (Doctor of Medicine)
Dr. Thomas P Nigra, Washington DC - MD (Doctor of Medicine)
Specialties:
Dermatology
Address:
110 Irving St NW SUITE 2B, Washington 20010
(202) 877-2848 (Phone), (202) 877-6292 (Fax)
Washington
110 Irving St NW, Washington 20010
(202) 877-7000 (Phone), (202) 877-8163 (Fax)
(202) 877-2848 (Phone), (202) 877-6292 (Fax)
Washington
110 Irving St NW, Washington 20010
(202) 877-7000 (Phone), (202) 877-8163 (Fax)
Certifications:
Dermatology, 1973
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
110 Irving St NW SUITE 2B, Washington 20010
Washington
110 Irving St NW, Washington 20010
MedStar Washington Hospital Center
110 Irving St North #West, Washington 20010
Washington
110 Irving St NW, Washington 20010
MedStar Washington Hospital Center
110 Irving St North #West, Washington 20010
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1967
Ny Hosp/Sloan-Kettering/Bel
Massachusetts General Hospital
Nih
Perelman School of Medicine University of Pennsylvania
Graduated: 1967
Ny Hosp/Sloan-Kettering/Bel
Massachusetts General Hospital
Nih
Thomas Peter Nigra, Washington DC
Thomas Peter Nigra, Washington DC
Specialties:
Dermatology, Family Medicine, Internal Medicine
Work:
Dermatology Associates
110 Irving St NW, Washington, DC 20010
110 Irving St NW, Washington, DC 20010
Education:
University of Pennsylvania(1967)
Methods And Compositions For Treating 5Alpha-Reductase Type 1 And Type 2 Dependent Conditions
Methods And Compositions For Treating 5Alpha-Reductase Type 1 And Type 2 Dependent Conditions
US Patent:
2008020, Aug 28, 2008
Filed:
Oct 20, 2004
Appl. No.:
11/885384
Inventors:
Glenn D. Hoke - Mt. Airy MD, US
Thomas P. Nigra - Washington DC, US
Thomas P. Nigra - Washington DC, US
International Classification:
A61K 31/7088, A61P 17/00, A61P 35/04, A61P 13/00
US Classification:
514 44
Abstract:
The invention relates generally to the use of anti-sense oligonucleotides, small interfering RNA, and ribozymes to modulate expression of the human steroid 5α-reductase gene and thereby modulate levels of dihydrotestosterone (DHT). Elevated levels of DHT are associated with various disorders including, but not limited to, skin diseases, hair loss, hirsuitism, and benign prostatic hyperplasia. The invention specifically relates to formulations of these anti-sense oligonucleotides, small interfering RNA, and ribozymes for administration to treat and prevent disorders